ZetrOZ Systems, LLC · Class II · Cleared Apr 28, 2026
| K-number | K260076 |
| Device name | SAM 3.0 Multi-Hour Continuous Ultrasound Device |
| Applicant | ZetrOZ Systems, LLC |
| Product code | PFW |
| Device class | Class II |
| Decision date | Apr 28, 2026 |
| Decision | Substantially Equivalent |
| Regulation | 890.5300 |
The SAM 3.0 is a home-use ultrasound device that applies continuous ultrasonic energy at 3 MHz to generate deep heat in body tissues. It is intended to treat selected musculoskeletal conditions including pain relief, muscle spasms, joint contractures, and circulatory improvements, with specific applications to knee osteoarthritis, chronic myofascial pain, and shoulder/elbow/ankle tendinopathy.
The SAM 3.0 is nearly identical to its predicate (SAM 2.0) with the same acoustic parameters: 3 MHz frequency, 0.65W single applicator or 1.3W dual applicator output, 4-hour maximum treatment duration, and 18,720 Joules maximum energy delivery. The primary differences are: added software control functions replacing solid-state IC chips, new LED indicators showing applicator warming and therapeutic heating status, and a slightly larger controller (2.34 cm vs 1.88 cm thickness) to accommodate an extended-capacity lithium battery.
IEC 60601-1-11 (2015) AMD 1 2020 for home healthcare environments; IEC 60601-1 ed. 3.2 (2020) for general safety and essential performance; IEC 60601-1-2 ed 4.1 (2020) for electromagnetic disturbances. Software testing was performed to demonstrate functional equivalency with the addition of control mechanisms and LED display functionality.
The SAM 3.0 is substantially equivalent to the SAM 2.0 predicate because both devices share identical intended use, indications, therapeutic parameters (frequency, power, duration, energy), physical dimensions (applicators and treatment heads), acoustic characteristics, and safety profiles. The SAM 3.0's added software controls and battery capacity represent minor design enhancements that do not alter the fundamental therapeutic mechanism or performance. The predicate's clinical efficacy from prior systematic literature review applies equally to the SAM 3.0.
View the full FDA submission: accessdata.fda.gov